Longs Drug Stores purchases Network Pharmaceuticals
June 19th 2006Longs Drug Stores has purchased the assets of Network Pharmaceuticals, including 21 retail pharmacies, one wholesale pharmacy, and one closed-door pharmacy, for about $10 million plus inventory. The retail pharmacies are located within or near medical office buildings, clinics, and hospitals.
Insurers to work for bimonthly Part D pay cycle
June 19th 2006America's Health Insurance Plans pledged to work with PBMs to ensure that payment for clean Part D claims is sent electronically or by mail at least twice monthly and no later than 30 days after the claims are submitted by the pharmacy. The industry will also work with PBMs and pharmacy to promote the availability and use of electronic funds transfer for Rx claims.
Disaster planning needed for Rx records
June 19th 2006A report on lessons learned from KatrinaHealth, the collaborative effort to post secure, on-line information about the Rx drug histories of Hurricane Katrina evacuees, has been posted at http://katrinahealth.org/katrinahealth.final.pdf. The Merkle Foundation's report urges the government and private sector to work together to put in place systems, technologies, and policies to ensure that information is readily available to patients and providers when disaster strikes.
MedVantx buys pharmacy service company
June 19th 2006MedVantx, a network promoting use of generics and OTC samples in physician offices, has acquired AmeriPharm, a pharmacy service company based in Sioux Falls, S.D. AmeriPharm will provide central distribution and automated medication replenishment for MedVantx' point-of-care Sample Center.
Seasonal depression patients now less SAD
June 19th 2006Wellbutrin XL (bupropion HCl extended-release tablets) from GlaxoSmithKline has been approved for the prevention of major depressive episodes in patients with a history of seasonal affective disorder (SAD) and is the first drug approved for this indication, the FDA said at a press conference. The depressive episodes associated with SAD can last up to six months and tend to occur during the autumn and winter, when daylight hours are at a minimum.
Beware of deadly street drug combo
June 19th 2006The Substance Abuse & Mental Health Services Administration (SAMHSA) has issued an alert to healthcare professionals who work with substance abuse patients about a new deadly drug combination being sold on the streets. Fentanyl is being combined with heroin or cocaine and has resulted in more than 100 deaths combined in the cities of Detroit, St. Louis, and Philadelphia since last September.
Contrast agent may be linked to nephrogenic fibrosis
June 19th 2006Gadolinium-containing contrast agents used at high doses may be linked to development of nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD) that occurs in patients with kidney failure. The FDA has learned of 25 cases of NSF/NFD in patients who received Omniscan, a gadolinium contrast agent, and then underwent a magnetic resonance angiography (MRA).
Zetia, fenofibrate combo OK'd for cholesterol lowering
June 19th 2006Merck/Schering-Plough Pharmaceuticals has announced the approval of a new indication for Zetia (ezetimibe). The drug can now be used in combination with fenofibrate, along with diet, for the reduction of high total cholesterol and LDL cholesterol in patients with mixed hyperlipidemia, a metabolic disorder consisting of high LDL cholesterol, low HDL cholesterol, and elevated triglycerides.
NIH: Effective ploys for tobacco cessation underused
June 19th 2006Effective tobacco cessation interventions are available and could double or triple quit rates, but not enough smokers request or are being offered these interventions. This was a key finding of an NIH panel that convened recently to assess the available scientific evidence on tobacco use prevention, cessation, and control.
Production of unapproved carbinoxamine items to cease
June 19th 2006The FDA has ordered manufacturers of all unapproved carbinoxamine-containing products to stop producing their offerings over the next 30 to 90 days. The agency has received 21 reports of death in children under two years of age associated with these products.
Educational campaign to launch for HFA transition
June 19th 2006The Allergy and Asthma Foundation of America (AAFA) will launch a campaign to educate patients and physicians to help ease the transition to hydrofluoroalkane (HFA) inhalers from the less environmentally friendly chlorofluorocarbon (CFC)-containing versions.
AMA adopts guidelines for in-store clinics
June 19th 2006The American Medical Association house of delegates has adopted a series of key principles to guide the establishment and operation of store-based healthcare clinics. The following principles are included in the guidelines: store-based health clinics must have a well-defined and limited scope of clinical services, consistent with state scope of practice laws; establish arrangements by which their healthcare practitioners have direct access to and supervision by physicians; and establish a referral system with physician practices or other facilities for appropriate treatment if the patients' condition or symptoms are beyond the scope of services provided by the clinic.
On-line college offers techs B.S. degree
June 19th 2006Excelsior College has launched an on-line bachelor's degree in health sciences for pharmacy technicians and other healthcare professionals seeking to advance into related positions in the health science professions. The program offers flexibility so students can continue to work while completing the course work at their own pace, according to the nonprofit distance education college located in Albany, N.Y.
R.Ph.s can help manage the cost of drugs
June 19th 2006Pharmacists are playing a key role in medical groups' efforts to manage prescription drug costs, according to a study prepared for the U S. Department of Health & Human Services by Abt Associates, Cambridge, Mass. Lead author Harmon Jordan, Sc.D., told Drug Topics, "Clinical pharmacists are helping to educate physicians and patients, and they're forming relationships with physicians where they seem to have a very synergistic existence."
Clinical Twisters: Treating depressive episode
June 19th 2006A 28-year-old woman, S.A. (two months' pregnant), is brought to your ER by her husband, who believes she is suicidal. According to your health-system medical records, S.A. was diagnosed with bipolar II disorder several years ago. She was previously treated with lithium and lamotrigine (Lamictal, GlaxoSmithKline) separately but was noncompliant. Her psychiatrist is weighing a mood stabilizer and/or antidepressant therapy during pregnancy. He asks for your recommendation.
Breakthroughs reported in controlling colon cancer
June 19th 2006Of the thousands of drug studies presented at the recent meeting of the American Association for Cancer Research (AACR) in Washington, D.C., two took center stage as "genuine breakthroughs in colon cancer treatment and prevention." First, international scientists cited the biologic panitumumab (Amgen) for extending progression-free survival in advanced cancer patients. Then they hailed new research on celecoxib's (Celebrex, Pfizer) potential to prevent colon cancer-despite concern about heart-related side effects.
USP proposes new 797 standards
June 19th 2006While most people haven't had time to digest the intricate details of the United States Pharmacopeia's proposed changes to General Chapter 797 (Pharmaceutical Compounding-Sterile Preparations), response to the protracted document has been almost universally positive.
New industry alliance fosters patient compliance
June 19th 2006Is it possible to raise public awareness about the value of medications while demonstrating the important role of community pharmacists in maximizing the effectiveness of drug therapy? The Pharmacy Value Alliance (PVA), a coalition of pharmaceutical companies and community pharmacy organizations, thinks so.
R.Ph.s told they can help shape nation's direction
June 19th 2006Pharmacy may be at a moment of unaccustomed visibility just at a time when the nation's direction is in flux, political commentators told the several hundred pharmacists who went to lobby Washington during the National Community Pharmacists Association's legislative conference last month.
Perfect Storm: Pharmacy seeks shelter from Medicaid disaster
June 19th 2006Still reeling from the economic havoc churned up by Medicare Part D's slower and lower reimbursements, pharmacy is bracing for the destruction swirling its way in the form of reimbursement cuts spawned by another monster storm named Medicaid.
Third new treatment option for MDS patients
June 19th 2006Myelodysplastic syndromes (MDS), a collection of disorders in which the bone marrow does not produce enough mature cells, has received a lot of attention in recent years despite the fact that it affects only about five in 100,000 people. This is due in part to the Food & Drug Administration's approval of several new molecular entities used in its treatment, including azacitidine (Vidaza, Pharmion) in 2004 and lenalidomide (Revlimid, Celgene) in 2005. And just last month the agency approved a third drug, decitabine injection (Dacogen, MGI Pharma).
New drug helps patients stub smoking
June 19th 2006The Food & Drug Administration recently approved varenicline (Chantix, Pfizer) as an aid to smoking cessation. Varenicline is the first new prescription treatment for smoking cessation to receive FDA approval in nearly a decade and only the second nicotine-free smoking cessation therapy ever approved by the agency. This new molecular entity received priority review because of its potential benefit to public health. Pfizer plans to make the drug available in U.S. retail pharmacies in the second half of 2006-most likely during the third quarter.
New drug approved in fight against Parkinson's
June 19th 2006The Food & Drug Administration has approved rasagiline (Azilect, Teva) for the treatment of Parkinson's disease (PD). Rasagiline is an irreversible monoamine oxidase type B (MAO-B) inhibitor that blocks the breakdown of dopamine, a chemical that transmits signals between the substantia nigra and other parts of the brain.